Last reviewed · How we verify
Dicinone (etamsylate)
Etamsylate (Dicinone), marketed by the First Affiliated Hospital of Zhejiang University, is a hemostatic agent with a key composition patent expiring in 2028. Its primary competitive advantage lies in its established market presence, though specific revenue figures are not available. The primary risk is the strong competition from same-class drugs such as romiplostim, eltrombopag, emicizumab, lusutrombopag, and avatrombopag, which are all patent-protected and have FDA approvals dating back to 2008.
At a glance
| Generic name | etamsylate |
|---|---|
| Sponsor | First Affiliated Hospital of Zhejiang University |
| Drug class | etamsylate |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparison of Etamsylate Versus Placebo to Prevent Bleeding in HSCT (PHASE3)
- Can Administration of Etamsylate Reduce Postpancreatectomy Hemorrhage (NA)
- Methods Decreasing Bleeding in Open Myomectomy (PHASE4)
- Comparison Study of Oxytocin Versus Tranexamic Acid and Etamsylaye Versus Placebo(Saline) (NA)
- Comparative Study Between Oxytocin Versus Tranexamic Acid and Ethamsylate (PHASE1,PHASE2)
- Tranexamic Acid and Ethamsylate For Preventing PPH in Patient Undergoing LSCS at High Risk For PPH (PHASE1,PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dicinone CI brief — competitive landscape report
- Dicinone updates RSS · CI watch RSS
- First Affiliated Hospital of Zhejiang University portfolio CI